Our previous research had demonstrated that valproic acid induces G0/G1 arrest of Kasumi-1 cells in t (8;21) acute myeloid leukemia
MS 275 (entinostat), FK228 (romidepsin) belongs to benzamide, and the depsipeptides group is used to inhibit class I HDACs
Clinical and Biological Effects of Valproic Acid as a Valproic acid (VPA) is an HDAC inhibitor and has been approved for treating epilepsy and bipolar disorders [15,16]
Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells
Valproic acid sodium is used in the
Lithium, a glycogen synthase kinase-3 (GSK-3) inhibitor, and VPA, a histone deacetylase (HDAC) inhibitor, have neuroprotective effects
Valproic acid is a first-line anti-epileptic drug and a proven HDAC inhibitor
27 VPA has also shown potent antitumour effects in a variety of in vitro Using an increase in histone acetylation as a biomarker of HDAC inhibition activity, MS275 was shown to be 30-times to 100-times more potent then valproic acid 209
In this study, we hypothesized that histone deacetylase (HDAC) inhibitor, valproic acid (VPA), can improve motor function by enhancing cell survival in PD genetic model mice with LRRK2 R1441G mutation
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Valproic acid (VPA; IUPAC: 2-propylpentanoic acid), the most clinically prescribed HDACi, is a fatty acid with anticonvulsant properties used for the treatment of epilepsy and seizures 26
Valproic acid (VPA), belonging to the short-chain fatty acid group of HDAC inhibitors, modulates the epigenome altering gene expression profiles across cell lines